S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?

Enovis (ENOV) Stock Price, News & Analysis

$62.45
+2.17 (+3.60%)
(As of 03/27/2024 ET)
Today's Range
$60.77
$62.50
50-Day Range
$58.49
$63.80
52-Week Range
$43.04
$66.14
Volume
322,746 shs
Average Volume
455,888 shs
Market Capitalization
$3.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$75.43

Enovis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
20.8% Upside
$75.43 Price Target
Short Interest
Bearish
8.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.78mentions of Enovis in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
18.22%
From $2.58 to $3.05 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.05 out of 5 stars

Medical Sector

349th out of 939 stocks

Surgical Appliances & Supplies Industry

9th out of 16 stocks

ENOV stock logo

About Enovis Stock (NYSE:ENOV)

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

ENOV Stock Price History

ENOV Stock News Headlines

ENOV Dec 2024 60.000 put
ENOV Mar 2024 60.000 put
The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
ENOV Jun 2024 50.000 put
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Q4 2023 Enovis Corp Earnings Call
Enovis Announces Fourth Quarter and Full Year 2023 Results
Enovis Announces Fourth Quarter and Full Year 2023 Results
Enovis Corporation Q4 2023 Earnings Preview
ENOV Mar 2024 70.000 call
5 Analysts Have This To Say About Enovis
See More Headlines
Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/27/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Employees
6,550
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$75.43
High Stock Price Target
$82.00
Low Stock Price Target
$70.00
Potential Upside/Downside
+20.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-33,260,000.00
Pretax Margin
-3.93%

Debt

Sales & Book Value

Annual Sales
$1.71 billion
Cash Flow
$6.63 per share
Book Value
$62.66 per share

Miscellaneous

Free Float
51,834,000
Market Cap
$3.41 billion
Optionable
Optionable
Beta
1.98
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

ENOV Stock Analysis - Frequently Asked Questions

Should I buy or sell Enovis stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ENOV shares.
View ENOV analyst ratings
or view top-rated stocks.

What is Enovis' stock price target for 2024?

8 equities research analysts have issued 12-month price targets for Enovis' shares. Their ENOV share price targets range from $70.00 to $82.00. On average, they expect the company's share price to reach $75.43 in the next year. This suggests a possible upside of 20.8% from the stock's current price.
View analysts price targets for ENOV
or view top-rated stocks among Wall Street analysts.

How have ENOV shares performed in 2024?

Enovis' stock was trading at $56.02 at the beginning of the year. Since then, ENOV stock has increased by 11.5% and is now trading at $62.45.
View the best growth stocks for 2024 here
.

When is Enovis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ENOV earnings forecast
.

How were Enovis' earnings last quarter?

Enovis Co. (NYSE:ENOV) released its quarterly earnings results on Thursday, February, 22nd. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.03. The company had revenue of $455 million for the quarter, compared to analyst estimates of $444.34 million. Enovis had a negative net margin of 1.95% and a positive trailing twelve-month return on equity of 3.84%. The company's quarterly revenue was up 11.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.72 EPS.

What ETFs hold Enovis' stock?
What guidance has Enovis issued on next quarter's earnings?

Enovis updated its FY24 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of $2.50-$2.65 for the period, compared to the consensus earnings per share estimate of $2.70. The company issued revenue guidance of $2.05-$2.15 billion, compared to the consensus revenue estimate of $2.02 billion.

Who are Enovis' major shareholders?

Enovis' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.98%), Vanguard Group Inc. (8.97%), Dimensional Fund Advisors LP (5.85%), DAVENPORT & Co LLC (3.44%), Channing Capital Management LLC (2.91%) and Allspring Global Investments Holdings LLC (1.89%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota.
View institutional ownership trends
.

How do I buy shares of Enovis?

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ENOV) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners